Ainnocence
Private Company
Funding information not available
Overview
Ainnocence is a private, next-generation biotech company that has developed a radical AI software system for drug discovery. Its core offering is a suite of AI platforms (SentinusAI®, CarbonAI®, etc.) designed to perform ultra-high-throughput virtual screening and multi-objective optimization for small molecules, proteins, cells, and other modalities. The company claims its technology can reduce discovery costs by up to 80%, screen 10 billion compounds per day, and achieve high wet-lab hit rates, positioning it as a potential enabler for tackling previously 'undruggable' targets. Led by a team with deep AI and biomedical expertise, Ainnocence operates as a platform technology provider to biopharma partners.
Technology Platform
Suite of generative AI platforms for therapeutic discovery across modalities (proteins, small molecules, peptides, cells, RNA, etc.), using proprietary sequence-based technology and a 1B+ parameter foundation model for ultra-high-throughput virtual screening and multi-objective optimization.
Opportunities
Risk Factors
Competitive Landscape
Ainnocence operates in a highly competitive field with numerous well-funded players like Recursion, Exscientia, Insilico Medicine, and others. Its claimed differentiation lies in its sequence-based, multi-modal AI suite and high virtual screening throughput. Success will depend on demonstrating superior predictive accuracy and tangible cost/time savings for partners.